Fetuin A Protein Scavenges Calcium to Protect Renal Tissue
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for renal disorders, particularly ischemic renal disorders, are inadequate, with existing therapeutic modalities providing controversial results or being emerging, and there is a need for effective agents to address ischemia reperfusion injury and related tissue damage.
Innovation Solution
Administration of Fetuin A, which acts as a 'mineral scavenger' and 'mineral chaperone' to clear calcium levels and mitigate inflammatory responses, thereby protecting renal tissue integrity and preventing fibrosis in ischemic conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapeutic modalities for ischemic renal disorders are used, then treatment options are available, but the results are controversial or the treatments are just emerging
Solution Approach 1:
The patent changes the therapeutic parameter by using Fetuin A, a plasma glycoprotein, instead of conventional therapeutic modalities. This parameter change enables direct targeting of the ischemia-reperfusion injury mechanism through Fetuin A's specific biological activities, resulting in reliable attenuation of tissue damage and fibrosis formation.
2Object-generated harmful factors
If Fetuin A is administered to clear calcium levels, then mineral scavenging effect is achieved, but the mechanism of action is not fully understood
Solution Approach 1:
The patent identifies Fetuin A as an intermediary substance that mediates between calcium accumulation and tissue damage. Fetuin A binds to calcium and other minerals, preventing their harmful effects while being cleared by the kidneys. This intermediary role explains both the beneficial effect (mineral scavenging) and the mechanism (binding and clearance).
Solution Approach 2:
The patent highlights that Fetuin A performs self-service by automatically binding to harmful minerals and facilitating their excretion through the kidney's filtration system. The protein's inherent ability to scavange minerals and its renal clearance mechanism provide a self-regulating protective effect without requiring external intervention.
3Speed
If reoxygenation is provided to ischemic tissue, then blood flow is restored, but tissue damage is exacerbated
Solution Approach 1:
The patent applies preliminary anti-action by administering Fetuin A before or during the ischemia-reperfusion event. Fetuin A pre-conditioning the tissue by binding to calcium and other minerals, thereby preventing the harmful effects of reoxygenation before they can occur. This preliminary protective action allows safe reoxygenation without tissue damage.
Solution Approach 2:
The patent converts the harmful effect of reoxygenation into a beneficial process by using Fetuin A to bind calcium and minerals that would otherwise cause damage during reoxygenation. The potential harm of mineral accumulation during reperfusion is transformed into a protective mechanism where Fetuin A scavenges these minerals, enabling safe restoration of blood flow.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Fetuin A effectively attenuates kidney tissue damage induced by hypoxic conditions and reduces fibrotic markers, demonstrating its potential in treating ischemic renal disorders by clearing calcium and modulating inflammatory cascades.
Implementation Method 1
Fetuin A acts as a 'mineral scavenger' and 'mineral chaperone' to clear calcium levels
Implementation Method 2
Fetuin A acts as a 'mineral scavenger' and 'mineral chaperone' to clear calcium levels and mitigate inflammatory responses
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 2A
AI summary
The present invention relates to Fetuin A (AHSG) for use in a method for treating a renal disorder, wherein an amount of Fetuin A effective for treating the renal disorder is administered to a subject in need thereof. The present invention further relates to a pharmaceutical composition for use in treating a renal disorder comprising Fetuin A and optionally at least one pharmaceutical acceptable carrier.